SGP8 (0, 100, and 500 µM; 24 h) modulates lipid metabolism, inflammation, and fibrosis [1]. It notably increases serum GLP-1 levels and exhibits inhibitory activity against DPP4 [1]. In L02 cells, Real-Time qPCR revealed that 24-hour incubation with SGP8 at concentrations of 0, 100, and 500 µM enhances the mRNA expression of lipid metabolism-related genes such as Cd36, Scd1, Cpt1, and Pparα while significantly decreasing the expression of inflammatory genes including Tnfα, Il-1β, and Ccl5. Western blot analysis demonstrated a decrease in the expression of lipid metabolism genes CD36, FAS, and SREBP-1 compared to a 1 mM PO model group. In LX2 cells, immunofluorescence analysis showed a significant reduction in the expression of TGFβ1-induced α-SMA and Collagen I proteins following a 24-hour incubation with 500 µM SGP8.

SGP8, administered at 15 mg/kg once daily via intraperitoneal injection for four weeks, alleviates steatohepatitis in mice on an MCD diet. Additionally, SGP8 at the same dosage over eight weeks mitigates liver damage and metabolic disorders in mice on an HFD. Tested on healthy 7-week-old male C57BL/6J mice (22 and 27 g), and dosed at 15 mg/kg daily for four weeks via intragastric administration, SGP8 did not reverse weight loss due to the MCD diet but reduced liver-to-body weight ratio, liver triglyceride and cholesterol content, serum ALT and AST activities, and improved liver fibrosis in MCD diet-induced NASH mice.